Who
Matthew Angel
CEO and President
Company insider
Files Form 4 as: CEO and President, Tempest Therapeutics; President and CEO, Ernexa Therapeutics.
In numbers
- Trades disclosed
- 12
- Buys
- 2
- Sells
- 0
- Bought
- $2.0M
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Aug 2022
- Last trade
- 24 Mar 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Mar 2026filed 23 Jun 2026 | TPST Tempest TherapeuticsBiotechnology | SEC FORM 4 Bought | $500K231,482 at $2.16 | filing |
| 24 Mar 2026filed 23 Jun 2026 | TPST Tempest Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —231,482 | filing |
| 24 Mar 2026filed 23 Jun 2026 | TPST Tempest Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —231,482 | filing |
| 24 Mar 2026filed 23 Jun 2026 | TPST Tempest Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —231,482 | filing |
| 24 Mar 2026filed 23 Jun 2026 | TPST Tempest Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —231,482 | filing |
| 24 Mar 2026filed 23 Jun 2026 | TPST Tempest TherapeuticsBiotechnology | SEC FORM 4 Bought | $500K231,482 at $2.16 | filing |
| 24 Mar 2026filed 25 Mar 2026 | TPST Tempest TherapeuticsBiotechnology | SEC FORM 4 Bought | $500K231,482 at $2.16 | filing |
| 24 Mar 2026filed 25 Mar 2026 | TPST Tempest TherapeuticsBiotechnology | SEC FORM 4 Bought | $500K231,482 at $2.16 | filing |
| 4 Feb 2026filed 6 Feb 2026 | TPST Tempest Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —269,621 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | TPST Tempest Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —269,621 at $0.00 | filing |
| 12 Jan 2023filed 13 Jan 2023 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —132,003 at $0.00 | filing |
| 1 Aug 2022filed 3 Aug 2022 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,487,003 at $0.00 | filing |
News
Tempest Therapeutics, Inc. (NASDAQ:TPST) Shares Shorted: Short Interest Up 73.6% in SeptemberTPST · dailypolitical.com · 17 Oct 2026Tempest Therapeutics (NASDAQ:TPST) Upgraded to "Sell" at Wall Street ZenTPST · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Matthew Angel; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.